E. Damiano

Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington’s Disease Patients—A Randomized Phase 2 Clinical Trial

Jamie L. Adams, L. Seeberger, H. D. Rosas, 2020, Journal of clinical medicine.

The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study

Emily M Beydler, Emily M. Page, C. Grillon, 2021, Psychopharmacology.

The Vasopressin 1a Receptor Antagonist SRX246 Reduces Aggressive Behavior in Huntington’s Disease

S. Hersch, M. Brownstein, H. Maibach, 2022, Journal of personalized medicine.

Human monoclonal antibody HA-1A binds to endotoxin via an epitope in the lipid A domain of lipopolysaccharide.

R. Siegel, M. Mascelli, B. Frederick, 1993, Journal of immunology.

HIV-1 Tat B-cell epitope vaccination was ineffectual in preventing viral rebound after ART cessation

G. Goldstein, E. Damiano, M. Pasha, 2012, Human vaccines & immunotherapeutics.

A proof-of-concept randomized crossover clinical trial of a first-in-class vasopressin 1a receptor antagonist for PTSD: Design, methods, and recruitment.

J. Kocsis, J. Difede, M. Brownstein, 2023, Contemporary clinical trials communications.